GenVivo to Present at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Presentations characterize GenVivo’s targeting vector development and safety data from a Phase 1 clinical trial of GEN2. PASADENA, CA, UNITED STATES, April 10, 2024 /EINPresswire.com/ -- GenVivo, Inc., a private clinical stage company with …